Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
1393 Views
eMediNexus 01 June 2020
Liver injury is increasingly being observed in patients with COVID-19, with an incidence ranging from 14-53%. A recent study by Ji et al evaluated the liver injury patterns and implication of non-alcoholic fatty liver diseases (NAFLD) on clinical outcomes in patients with COVID-19.
From January 20 till February 17, 2020, investigators assessed consecutive patients admitted to two designated COVID-19 Hospitals in China with confirmed COVID-19 and information on NAFLD status. Liver injury was defined as hepatocellular if the alanine aminotransferase (ALT) level was >30 IU/L for males and >19 IU/L for females; ductular if alkaline phosphatase (ALP) was >the upper limit of normal (ULN) along with gamma-glutamyltransferase (GGT) >ULN; mixed if both hepatocellular and ductular enzymes were raised >ULN. NAFLD was defined by a hepatic steatosis index (HSI = 8 × [ALT/AST] + BMI [+ 2 if type 2 diabetes yes, + 2 if female]) of >36 points and/or by abdominal ultrasound examination. The ALT/AST value for HSI was obtained either at complete recovery on discharge or from records of the patients before and within 12 months of the diagnosis of COVID-19. The patients were followed until discharged with recovery or disease progression.
Two hundred and two consecutive patients were involved in this study. Liver injury was observed in 50% patients on admission and 75.2% during hospitalization. Nearly all liver injury was assessed as mild with hepatocellular pattern. Only 2.6% (4/152) had ductular or mixed pattern. About 33.2% had persistent abnormal liver function from admission to last follow-up. Progressive disease was evident in 19.3% while stable disease was noted in 80.7% patients. Patients with progressive disease were noted to be older, have higher BMI, and a higher percentage of comorbidity and NAFLD. According to the univariate and multivariate logistic regression analysis, male sex (odds ratio [OR] 3.1; 95% CI 1.1–9.4), age >60 years (OR 4.8; 95% CI 1.5–16.2), higher BMI (OR 1.3; 95% CI 1.0–1.8), underlying comorbidity (OR 6.3; 95% CI 2.3–18.8) and NAFLD (OR 6.4; 95% CI 1.5 - 31.2), had a link with COVID-19 progression.
There was higher risk of disease progression (6.6% [5/126] vs. 44.7% [34/76]), higher odds of abnormal liver function from admission to discharge (70% [53/76] vs. 11.1% [14/126]) and longer viral shedding time (17.5 ± 5.2 days vs. 12.1 ± 4.4 days) in NAFLD patients in comparison with patients without NAFLD.
Source: Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. Journal of Hepatology April 8, 2020.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}